During 2021 and 2022, eight field-collected and five laboratory strains with varying susceptibility to different Bt proteins were evaluated for their responses against HearNPV using diet-overlay bioassays. The five laboratory strains included SS (susceptible to all Bt proteins), CRY-RR (resistant to Cry1 and Cry2), VIP-RR-70 (resistant to Vip3Aa), VIP-RR-15 (resistant to Vip3Aa), and TRE-RR (resistant to Cry1, Cry2, and Vip3Aa). Our findings showed that the susceptibility of TRE-RR, VIP-RR-70, and VIP-RR-15 strains to HearNPV was similar to that of the SS strain.
View Article and Find Full Text PDFBackground: Development of pyriproxyfen and neonicotinoid resistance in the B-biotype whitefly and recent introduction of the Q biotype have the potential to threaten current whitefly management programs in Arizona. The possibility of integrating the novel anthranilic diamides chlorantraniliprole and cyantraniliprole into the current program to tackle these threats largely depends on whether these compounds have cross-resistance with pyriproxyfen and neonicotinoids in whiteflies. To address this question, the authors bioassayed a susceptible B-biotype strain, a pyriproxyfen-resistant B-biotype strain, four multiply resistant Q-biotype strains and 16 B-biotype field populations from Arizona with a systemic uptake bioassay developed in the present study.
View Article and Find Full Text PDF